Biographies

Mr. Kevin C. Tang is Chairman of the Board, Chief Executive Officer of the company since 2013. Mr. Tang also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002 and an affiliate of the Company. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. Since 2009, Mr. Tang has served as a director of Heron Therapeutics, Inc. and, since 2012, has served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he was a director of Trimeris, Inc. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

Dr. Jeff L. Vacirca M.D. is Vice Chairman of the Board of the company since July 2016, as a director since January 2017, and, from March 2017 to September 2017, served as our Chief Medical Officer. Since 2008, Dr. Vacirca has served as Chief Executive Officer and Managing Partner/Director of Clinical Research at New York Cancer Specialists. Since 2014, he has served on the Scientific Advisory Board of Caris Life Sciences. Dr. Vacirca currently serves as the President of Community Oncology Alliance, a non-profit organization dedicated to advocating for community oncology practices and patients with cancer. Dr. Vacirca received a B.A. degree in human biology from the University at Albany and an M.D. degree from St. George’s University.

Mr. John G. Lemkey is Chief Financial Officer of the company since 2013. Since 2012, Mr. Lemkey has served as Chief Operating Officer of Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company, which Mr. Lemkey joined in 2006. From 2003 to 2006, Mr. Lemkey was a Senior Auditor at Ernst & Young LLP. Mr. Lemkey received a B.S. degree in accounting from the University of Southern California and is a Certified Public Accountant (inactive) in the state of California.

Mr. Robert D. Millham is Chief Operating Officer of the company since July 2017. From 2015 to 2017, Mr. Millham served as Senior Vice President and General Manager, Hematology and Oncology at inVentiv Health Clinical, LLC. From 1998 to 2015, Mr. Millham held various positions at Pfizer Inc., serving most recently as Vice President of Clinical Operations for Oncology and previously as Senior Director, Early Development Team Leader. Mr. Millham received a B.A. degree in biology from Middlebury College, an M.S. degree in microbiology from the University of New Hampshire and an M.Sc. degree in pharmaceutical medicine from Hibernia College.

Mr. Stewart M. Kroll is Senior Vice President - Biometrics of the company since October 2016. From 2005 to 2016, Mr. Kroll held various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation. From 1997 to 2000, Mr. Kroll held various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. Mr. Kroll received an M.A. degree and B.A. degree in statistics from the University of California, Berkeley.

Mr. Thomas Wei is Senior Vice President - Research and Strategy of the company since 2015. Mr. Wei also is Managing Director at Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company, which he joined in 2015. From 2009 to 2015, he served as a Managing Director and biotechnology equity research analyst at Jefferies LLC. From 2003 to 2009, Mr. Wei was a biotechnology equity research analyst at Piper Jaffray, most recently serving as Managing Director. From 1998 to 2003, Mr. Wei was a biotechnology equity research analyst at Deutsche Bank AG and Adams, Harkness & Hill Inc. Mr. Wei received an A.B. degree in biochemical sciences from Harvard University and an M.B.A. degree from Oxford University.

Ms. Natasha M. Bartasch-Price is Vice President - Program Management of the company since October 2017. From 2016 to 2017, Ms. Bartasch-Price served as Vice President, Global Project Management and Managing Director, Patient Recruitment and Retention at Bioclinica, Inc. From 2000 to 2016, Ms. Bartasch-Price held various positions at Pfizer Inc., most recently serving as Senior Director, Clinical Operations Program Lead. Ms. Bartasch-Price received a B.S. degree in biology from Shippensburg University and an M.B.A. degree from Eastern University.

Ms. Nicole H. Gollaher, J.D. is Vice President - Legal Affairs of the company since October 2017. From 2006 to 2017, Ms. Gollaher was self-employed in private practice representing both large and small biotechnology, pharmaceutical and medical device companies, including working on a contract basis for Pfizer Inc. From 1996 to 2004, she was an Associate at Wiggin and Dana LLP. Ms. Gollaher received a B.A. degree in international relations and history from Brown University and a J.D. from the University of Connecticut.

Ms. Valerie L. Legagneur is Vice President - Clinical Operations of the company since December 2016. From 2006 to 2016, Ms. Legagneur held various positions at Pfizer Inc., most recently serving as Director and Clinical Operations Program Lead for the Hematology portfolio. From 2004 to 2006, she served as Project Manager of Clinical Operations at Pharmaceutical Product Development, LLC. From 2002 to 2004, Ms. Legagneur served as a Regional Clinical Research Associate at Advanced Biologics, LLC. From 2001 to 2002, she served as a Clinical Research Assistant at Sanofi-Aventis Research. Ms. Legagneur received an M.A. degree and a B.A. degree from Stony Brook University and is an S.O.C.R.A. Certified Clinical Research Professional.

Dr. Steven S. Pfeiffer, Ph.D. is Vice President - Technical Operations of the company since August 2016. From 2015 to 2016, Dr. Pfeiffer was at Horizon Pharma PLC, most recently serving as Senior Director of Manufacturing and Development. From 2011 to 2015, he held various positions at Kythera Biopharmaceuticals, Inc., most recently serving as Associate Director of Product Research, Development and Manufacturing. From 2009 to 2010, Dr. Pfeiffer served as Associate Director at Sai Advantium Pharma Limited. From 2005 to 2009, he held various positions at Gilead Sciences, Inc., most recently serving as a Research Scientist II. Dr. Pfeiffer received a Ph.D. degree in chemistry from the University of California, Santa Barbara, an M.B.A. degree from California State University, East Bay, and a B.S. degree in chemistry from the University of Arizona.

Mr. Joseph P. O'Connell M.D. is Chief Medical Officer of the company since September 2017. From 2015 to 2017, Dr. O’Connell served as Vice President, Medical and Scientific Affairs, Hematology and Oncology at inVentiv Health Clinical, LLC. From 2007 to 2015, Dr. O’Connell held various positions at Pfizer Inc., most recently serving as Senior Director and Asset Global Clinical Lead for Oncology. Prior to 2007, he practiced adult medical oncology for more than 15 years, most recently as a Medical Oncologist at the Yale Cancer Center. Dr. O’Connell received a B.S. degree in biology from Fordham University and an M.D. degree from the State University of New York.

Mr. Robert Harvey Rosen is Director of the company since July 2017. Since 2013, Mr. Rosen has served as President and as a director of Heron Therapeutics, Inc., and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. Since 2014, he has served as a director of La Jolla Pharmaceutical Company. From 2014 to 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, he served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From 2011 to 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

Dr. George F. Tidmarsh is Director of the company since December 2016. Since 2012, Dr. Tidmarsh has served as President, Chief Executive Officer and director of La Jolla Pharmaceutical Company. In 2005, Dr. Tidmarsh founded Horizon Pharma, Inc., where he served as President and Chief Executive Officer until 2008 and as a director and consultant until 2011. In 2001, he founded Threshold Pharmaceuticals, Inc., where he served as President until 2005. From 1996 to 2000, Dr. Tidmarsh held various senior positions at Coulter Pharmaceutical, Inc., most recently serving as Chief Medical Officer. Earlier in his career, Dr. Tidmarsh held various scientific and clinical positions at Sequus Pharmaceuticals, Inc., Gilead Sciences, Inc. and SyStemix, Inc. Dr. Tidmarsh received a Ph.D. degree and M.D. degree from the Stanford University School of Medicine and a B.S. degree in microbiology from Stanford University.

Mr. Aaron I. Davis is Independent Director of the company since December 2016. Mr. Davis has been the Chief Executive Officer of Boxer Capital, the healthcare arm of Tavistock Group, since 2012. Mr. Davis co-founded Boxer Capital in 2005 and, prior to being appointed Chief Executive Officer, served as Portfolio Manager. Since 2016, Mr. Davis has served as a director of CiVi Biopharma, Inc. From 2006 to 2008, he served as a director of Kalypsys, Inc. From 2000 to 2004, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University.

Mr. Craig A. Johnson is Independent Director of the company since July 2017. Mr. Johnson also is a director of Heron Therapeutics, Inc., La Jolla Pharmaceutical Company, Mirati Therapeutics, Inc. and GenomeDx Biosciences, Inc. Mr. Johnson also served as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012, and as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014. From 2011 to 2012, he served as Chief Financial Officer of PURE Bioscience, Inc., and, from 2010 to 2011, Mr. Johnson served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, he served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc., and, from 2009 to 2010, as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: